Feb 28 |
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
|
Feb 26 |
Weight-Loss Tizzy: Why Altimmune Surged 27% As Others Tumbled On A New Study
|
Feb 23 |
1 Beaten-Down Stock That Could Soar by 40%, According to Wall Street
|
Feb 14 |
Paulson & Co. bolsters stakes in Newmark, NovaGold, Madrigal Pharmaceuticals
|
Feb 13 |
15 Best Strong Buy Stocks To Invest In
|
Feb 10 |
Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown
|
Feb 8 |
Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine
|
Feb 8 |
Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade)
|
Feb 7 |
Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential
|
Feb 6 |
Eli Lilly hurts NASH drug developers after mid-stage win for obesity therapy
|